Explore our portfolio of clinical trials dedicated to cervical cancer research. These trials focus on improving diagnostic methods, developing new treatments, and optimizing patient management to enhance outcomes.
This resource is intended for patients, healthcare professionals, and researchers seeking up-to-date information on ongoing and completed studies within the NSGO-CTU network.
For detailed eligibility criteria, site information, or additional inquiries, please contact the assigned Project Manager.
ENGOT-CX6
A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax® – TF-ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer.
ENGOT-CX8
A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® -TF-ADC) Monotherapy and in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer.
ENGOT-CX11
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer.
ENGOT-CX12
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer.
ENGOT-CX19/eVOLVE
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicentre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
ENGOT-CX20/TroFuse-020
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer